Copyright © Inderes 2011 - present. All rights reserved.

Optomed

2.41 EUR

+1.05 %

5,655 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+1.05 %
-9.91 %
-36.07 %
-36.07 %
-34.78 %
-37.65 %
-38.68 %
-60.36 %
-47.38 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
51.7M EUR
Turnover
96.2K EUR
P/E (adj.) (26e)
-14.49
EV/EBIT (adj.) (26e)
-14.06
P/B (26e)
2.53
EV/S (26e)
2.62
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
3.80 EUR
Updated
11.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 11.02.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5
2026

Interim report Q1'26

8.5
2026

General meeting '26

14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q4'25 preview: Fokus på forventninger
Analyst Comment by
Juha Kinnunen

Optomed Q4'25 preview: Fokus på forventninger

Optomed offentliggør sit Q4 regnskab næste tirsdag. Hovedfokus i regnskabet er rettet mod omsætningsvækstprognosen for 2026, som vi forventer vil være i form af "stærk vækst". Vores opmærksomhed i regnskabsmeddelelsen er især rettet mod den kommercielle udvikling af vækstfaktorerne i Udstyr-segmentet, såsom Aurora AEYE-løsningen og Optomed Lumo.

Optomed
Forum discussions
Optomed’s added value is that it is the only FDA-approved portable fundus camera capable of AI diagnosis. This is no small feat in a market where approval is a prerequisite for participation. If one doesn’t see this as added value or doesn’t believe the market will be broadly interested...
20 hours ago
by Due Diligence
18
Zeiss as a comparison is an interesting choice. It’s worth considering, for example, for which company doubling or tripling sales is realistic? A billion-dollar company or Optomed, which is almost in a startup phase? A company that has opened up a continuously billed US market after...
21 hours ago
by Due Diligence
17
You don’t have to do that between every image, do you? What do you mean? I have a completely different understanding of these devices. MRI equipment is also transported on the road, and it certainly has more delicate and calibration-intensive technology. And whether it’s portable...
19 hours ago
by Clark kent
10
Totally possible. But one shouldn’t build an entire view on anecdotal evidence, one way or another.
19 hours ago
by Clark kent
7
On the other hand, I heard that an ophthalmologist praised Aurora as a revolutionary device. He praised its ease of use, among other things.
19 hours ago
by Tobias
5
It’s good to come here sometimes to offer another perspective and challenge, to “stir the ant’s nest,” so to speak. From Lumo (or in the CEO’s speeches), there could be, or it has been mentioned, that the camera would be a platform with many different AI algorithms, and if the camera...
20 hours ago
by BossoB
5
I was discussing the Lumo Aeye FDA process with Grok. Mr. Grok stated that approval could be obtained in Q4 2026 or Q1 2027. What are your thoughts on Grok’s report? ““““““““““ Yes, I fully understand your point – and the answer is partly yes, partly no. In a 510(k) process like ...
1 hour ago
by j.sälli
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.